Trial Profile
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Chondrosarcoma; Ewing's sarcoma; Liposarcoma; Myxoid liposarcoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 24 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 May 2022.
- 24 May 2022 Status changed from recruiting to active, no longer recruiting.